1. Introduction {#sec1-ijms-21-05164}
===============

Nuclear factor kappa B (NF-κB) signaling has been well studied for more than three decades from the first report by Sen et al. \[[@B1-ijms-21-05164]\] in 1986. It is implicated in both normal physiology \[[@B2-ijms-21-05164],[@B3-ijms-21-05164]\] and in the development of a multitude of diseases \[[@B4-ijms-21-05164]\] ranging from inflammation \[[@B5-ijms-21-05164],[@B6-ijms-21-05164]\], cancer \[[@B7-ijms-21-05164],[@B8-ijms-21-05164],[@B9-ijms-21-05164]\] to autoimmune disorders \[[@B10-ijms-21-05164],[@B11-ijms-21-05164]\]. Thus, it is not surprising that many researcher groups are actively pursuing efforts to modulate this pathway for therapeutic intervention. Despite the vast knowledge for this pathway and several compounds in preclinical stage still there is a dearth of clinically proven molecules. As a case in point, Gilmore et.al. \[[@B12-ijms-21-05164]\] enlisted 785 inhibitors of NF-κB signaling in 2006 but only few of them did even reach clinical trials. In this review, we aim to analyze the small molecule inhibitors of NF-κB pathways that were taken into clinical trials.

NF-κB family consists of five transcription factors: NF-κB1/p50, NF-κB2/p52, RelA/p65, RelB and c-Rel that homodimerize or heterodimerize to 15 NF-κB complexes \[[@B13-ijms-21-05164]\]. These are mainly found in the cytoplasm of resting cells and upon activation they translocate to the nucleus for transcription which in-turn leads to direct or indirect activation or repression of hundreds of genes. Notwithstanding their ubiquitous nature, they show high contextual diversity for transcription based on the tissue type and specific biological circumstances \[[@B14-ijms-21-05164]\].

The NF-κB pathway can be triggered by diverse stimuli that includes inflammatory cytokines, immune signals and antigens, microbial products and stress signals \[[@B15-ijms-21-05164]\]. Upon stimulation, either the canonical or the non-canonical pathway ([Figure 1](#ijms-21-05164-f001){ref-type="fig"}) is activated, depending on the type of Inhibitor of κB (IκB) protein or IκB kinase (IKK) complex involved. The biology of this signaling cascade is well reviewed in the literature \[[@B16-ijms-21-05164],[@B17-ijms-21-05164]\]. On stimulation of the receptor, canonical pathway mediated through adapter proteins and kinases, activates IKK complex that comprises of IKKα/β/γ. Polyubiquitination and site-specific phosphorylation subsequently lead to proteasomal degradation of IκB protein and release of NF-κB dimers for translocation to the nucleus. Furthermore, the pathway mediated by NF-κB1/p50, also involves partial degradation of p105 to p50. Non-canonical pathway \[[@B18-ijms-21-05164],[@B19-ijms-21-05164]\], on stimulation recruit tumor necrosis factor (TNF) receptor-associated factor (TRAF) and cellular inhibitor of apoptosis (c-IAP) as TRAF2/TRAF3/c-IAP1/2 complex. NF-κB-inducing kinase (NIK), that is constitutively bound to the complex, on activation dissociates, gets stabilized and phosphorylate IKKα homodimer. This leads to partial degradation of p100 to p52 and the RelB/p52 heterodimer translocate to nucleus for further transcription \[[@B20-ijms-21-05164]\].

At homeostasis, NF-κB pathways are essential for regulating host defense responses against stress, injury and infection \[[@B13-ijms-21-05164]\]. The pathways that are normally transient and self-limiting, have been shown to be excessively or constitutively active under disease condition. Dysregulation of NF-κB leads to the pathogeneses of cancer, inflammation, diabetes, and autoimmune disorders \[[@B13-ijms-21-05164],[@B17-ijms-21-05164],[@B18-ijms-21-05164],[@B21-ijms-21-05164]\]. It is also implicated in the refraction of current therapies in both oncological \[[@B22-ijms-21-05164],[@B23-ijms-21-05164]\] and non-oncological conditions \[[@B24-ijms-21-05164]\]. These findings have generated very high interest in targeting the NF-κB pathway, but the real challenge exists in overcoming its ubiquitous physiological functions and have only contextual, tissue specific function \[[@B25-ijms-21-05164],[@B26-ijms-21-05164],[@B27-ijms-21-05164]\].

NF-κB signaling cascades can be modulated at stages involving the receptor, IKK complex, gene transcription, post-translation or at any stage in between ([Figure 2](#ijms-21-05164-f002){ref-type="fig"}). This has been accomplished \[[@B4-ijms-21-05164],[@B28-ijms-21-05164]\] using small molecules, peptides, oligonucleotides, monoclonal antibodies (mAbs), and small interfering RNA (siRNA). Among these drugs, small molecules are of special interest due to the ease of designing, synthesizing and amending in drug development research \[[@B29-ijms-21-05164],[@B30-ijms-21-05164]\]. Though riddled with challenges of selectivity, multiple targets and adverse drug reaction (ADR) in clinic, modern school of thoughts now encourage a molecule to hit multiple targets for a desired efficacy and to avoid resistance \[[@B31-ijms-21-05164]\]. Moreover, even with the rising importance of biologic drugs in drug discovery, 76% of US-FDA (Food and Drug Administration-US) approved drugs in the last decade were still small molecules \[[@B32-ijms-21-05164]\]. This encouraged us to review information regarding clinically relevant small molecule inhibitors of the NF-κB pathway from cell membrane receptor stimulation to nuclear signaling. Apart from evaluating the successes and failures of these small molecule NF-κB inhibitors during clinical trials, we also reviewed drugs that have been re-purposed after being shown to have NF-κB activity. We have consciously excluded herbal extract that often involves multiple components, but included small molecules isolated from natural products. Furthermore, we have focused only on modalities that inhibit the pathway as it has seen more clinical success than those activating cascade. Special emphasis has been given to molecules that were withdrawn or discontinued and the probable reason, if the same is disclosed in public domain. Molecules in clinical trials held-up at a stage with no further reports are often taken as drop-outs, but we have cannot consider them to be withdrawn due to absence of any credible information.

2. Molecules that Inhibit Upstream IKK Complex in NF-κB Pathway {#sec2-ijms-21-05164}
===============================================================

2.1. Inhibition of Cell Membrane Receptor Targets {#sec2dot1-ijms-21-05164}
-------------------------------------------------

NF-κB signaling cascade are mostly initiated at the cell membrane through tumor necrosis factor-α receptor (TNFR), interleukin1 receptor (IL1R), toll-like receptor (TLR), T-cell receptors (TCR), B-cell receptors (BCR), growth factor receptors and TNF receptor superfamily (TNFRSF), such as lymphotoxin (LT) α/β, cluster of differentiation (CD) 27, CD30, CD40, receptor activator of NF-κB (RANK), fibroblast growth factor-inducible 14 (Fn14), and B-cell activating factor (BAFF) receptors \[[@B33-ijms-21-05164]\]. The cell surface receptors are most ideal targets to inhibit most of the pathways, but involved generally in protein--protein interaction (PPI), they lack binding sites for small molecules. They are mostly targeted by antibodies, siRNA, oligonucleotides, or peptides. With the advancement in biology, designing molecules to inhibit these receptors has become a lot easier and relatively smaller oligonucleotides or peptides have also been explored. Currently in the market, many drugs targeting the receptors are biologics such as mAbs and recombinant/fusion protein \[[@B34-ijms-21-05164],[@B35-ijms-21-05164],[@B36-ijms-21-05164]\]. Viz, TNF blockers (Adalimumab, Certolizumab pegol, Etanercept and Infliximab), IL1R antagonist (Anakinra, Canakinumab), CD30 chimeric mAbs (Brentuximab vedotin), RANK ligand inhibitors (Denosumab). TNFR and IL1R mAbs are well-established and approved for various clinical indications, whereas in small molecule inhibitors, there is only one preclinical candidate. UCB-6786 by UCB pharma, a TNFR small molecule inhibitor, has only been tested for in vivo efficacy in collagen antibody induced arthritis mice model \[[@B37-ijms-21-05164]\].

TLR signaling has been immensely studied for several years due to its indispensable role in various disease conditions such as cancer, inflammatory and autoimmune diseases. Both TLR agonist and TLR antagonist biologics have been testing extensively in clinical trials \[[@B38-ijms-21-05164]\]. Focusing small molecule inhibitors, some TLR 4 and TLR7/8/9 antagonists have successfully entered various stages of clinical trials ([Table 1](#ijms-21-05164-t001){ref-type="table"}). TLR7/8/9 antagonists are mostly antisense oligonucleotide (ASO) like Bazlitoran (IMO-8400), which was granted orphan drug status \[[@B39-ijms-21-05164]\] for diffuse large B cell lymphoma (DLBCL) and Waldenstrom's Macroglobulinemia (WM). However, further studies were suspended for both indications \[[@B40-ijms-21-05164]\]. Other ASO molecules such as IMO-3100 and IMO-9200, also did not go beyond phase 2 and phase 1 stage respectively. Only one small molecule TLR7/8/9 antagonist, CPG-52364 developed by Coley Pharmaceutical Group was taken into phase 1 trial for systemic lupus erythematosus (SLE) but was discontinued in 2010 (<https://clinicaltrials.gov/ct2/show/NCT00547014>). TLR4 antagonist, JKB-121, a small molecule inhibitor developed by TaiwanJ Pharmaceuticals for the non-alcoholic steatohepatitis (NASH) indication, is in jeopardy after it failed to demonstrate efficacy in a phase 2 placebo-controlled trial due to surprising positive response in the placebo arm \[[@B41-ijms-21-05164]\]. In January 2019, JKB-122, another small molecule inhibitor of TLR 4, was reported to produce positive results from a phase 2 clinical trial evaluating its efficacy and safety during the treatment of patients with refractory autoimmune hepatitis. Moreover, the drug was demonstrated to be safe and well-tolerated in this study. As an orphan drug designation, the study results of JKB-122 provide a further opportunity for the autoimmune hepatitis (AIH) treatment \[[@B42-ijms-21-05164]\] ([Table 1](#ijms-21-05164-t001){ref-type="table"}).

Many TNFRSF inhibitors are successfully undergoing clinical trials for various indications including RANK ligand (RANKL) inhibitors. RANK signaling essential for the activation of osteoclasts, is mediated through the activation of the c-jun N-terminal kinase (JNK) and NF-κB pathways. Although RANK is activated by RANKL \[[@B43-ijms-21-05164]\], it has been reported that even overexpression of RANK may itself activate the NF-κB pathway. Modulating the RANKL-RANK signaling axis has been a key strategy for diseases like osteoclastogenesis, bone destruction and even for many cancers \[[@B35-ijms-21-05164]\]. Denosumab is a human recombinant monoclonal antibody against RANKL that has achieved orphan drug status \[[@B44-ijms-21-05164]\] for bone cancer and malignant hypercalcemia and is currently marketed for these disease conditions along with other bone disorders, bone metastases, corticosteroid-induced osteoporosis, and male osteoporosis \[[@B45-ijms-21-05164],[@B46-ijms-21-05164]\]. It is currently in phase 3 for breast cancer and non-small cell lung cancer (NSCLC) but there are concerns of increased risk of spontaneous multiple vertebral fractures upon denosumab discontinuation that has to be managed by bisphosphonate \[[@B47-ijms-21-05164]\]. Most other molecules in clinical trials are also antibodies or nanobodies like JMT-103, IBI-307, and ALX-0141. Osteoprotegerin (OPG), a natural peptide that binds to the cytokine RANKL and prevents it from binding to RANK, has also been used to modulate this pathway. Amgen explored recombinant osteoprotegerin (AMGN-0007) but discontinued further studies on this molecule after incidents for bone disorders, cancer pain, postmenopausal osteoporosis, and RA. Similarly, Teva was developing an OPG analogue, CEP-37251, discovered by EvoGenix, and took it to phase 1 for osteoporosis but it was terminated. There is no small molecule inhibitor of RANKL in clinic, but with a better understanding of PPI disrupters, we expect to see one soon \[[@B48-ijms-21-05164]\]. Similarly, other TNFRSF such as BAFF, LTβ, CD27, CD30, CD40, OX40, and Fn14 also do not have any small molecule inhibitor in development.

ijms-21-05164-t001_Table 1

###### 

Clinical small molecule inhibitors of cell membrane receptors in NF-kB pathway.

  Drug                                           Originator/Developer                                        Stage               Indication                                                   Trail No.                  Other Information
  ---------------------------------------------- ----------------------------------------------------------- ------------------- ------------------------------------------------------------ -------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Toll like Receptor 4 (TLR4) antagonist***                                                                                                                                                                           
  Ibudilast (MN-166)                             MediciNova Inc                                              Marketed in Japan   Allergic conjunctivitis, Asthma, Cerebrovascular disorders   NCT01860807; NCT04057898   Nonselective phosphodiesterase inhibitor.Neuroprotective benefit observed in clinic.Common side effects are nasopharyngitis and headache.Nausea and depression at higher doses.
  Phase3                                         Amyotrophic Lateral Sclerosis                               NCT04057898                                                                                                 
  Phase 1/2                                      Glioblastoma                                                NCT03782415                                                                                                 
  MediciNova Inc/NIH                             Phase 2                                                     MS                  NCT01982942                                                                             
  JKB-122                                        Jenken Biosciences/TaiwanJ Pharmaceuticals                  Phase 3             Autoimmune Hepatitis                                         NCT04371718                Out licensed to Newsoara Biopharma for clinical development of JKB-122 and for preclinical research of JKB-133.Successfully achieved primary endpoint in phase 2 Autoimmune Hepatitis study.Study in HCV patients terminated after completing phase 1.
  Phase 2                                        Autoimmune Hepatitis                                        NCT02556372                                                                                                 
  Phase 2                                        Chronic hepatitis C                                         NCT02293941                                                                                                 
  Phase 2                                        NASH                                                        NCT04255069                                                                                                 
  VB-201 (TLR2/4 antagonist)                     VBL Therapeutics                                            Phase 2             Psoriasis                                                    NCT01001468; NCT01837420   Did not meet primary endpoint in Psoriasis and Ulcerative Colitis \[[@B49-ijms-21-05164]\].Currently in preclinical trials for Non-alcoholic fatty liver disease.
  Phase 2                                        Ulcerative colitis                                          NCT01839214                                                                                                 
  JKB-121                                        Manal Abdelmalek, Duke University/TaiwanJ Pharmaceuticals   Phase 2             NASH                                                         NCT02442687                Failed to demonstrate efficacy due to surprising positive response in the placebo arm and discontinued for NASH.
  ***Toll like Receptor 7 (TLR7) antagonist***                                                                                                                                                                           
  CPG-52364                                      Pfizer                                                      Phase 1             Healthy Volunteers (For SLE)                                 NCT00547014                Discontinued for SLE in Jan2020.

Abbreviations: ALT---alanine aminotransferase; MS---multiple sclerosis; NASH---Non-alcoholic steatohepatitis; NIH---National Institutes of Health; SLE---systemic lupus erythematosus.

2.2. Inhibition of Receptor Adaptor Protein {#sec2dot2-ijms-21-05164}
-------------------------------------------

### 2.2.1. Bruton's Tyrosine Kinase (BTK) Inhibitors {#sec2dot2dot1-ijms-21-05164}

BTK and other Tec family of non-receptor tyrosine kinases act as a platform for bringing together a diverse array of signaling proteins. Among the Tec family kinases, BTK is one of the successfully explored targets with almost 50 molecules entering clinical trials and a couple of others launched for multiple indication \[[@B50-ijms-21-05164],[@B51-ijms-21-05164]\].

Small molecule inhibitor, Ibrutinib was developed for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), graft-versus-host disease (GVHD), marginal zone lymphoma (MZL), and WM. However, this molecule was terminated for further evaluation during the studies of many other cancers at different stages, including breast cancer, rheumatoid arthritis (RA), and seasonal allergic rhinitis (SAR). Acalabrutinib is currently marketed for MCL and in collaboration with AstraZenca was recently approved \[[@B52-ijms-21-05164]\] (Nov.2019) for CLL or small lymphocytic lymphoma (SLL). Zanubrutinib was recently granted \[[@B53-ijms-21-05164]\] an accelerated approval by the US-FDA for MCL as a second line of therapy and preregistered for CLL ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

Many other superior BTK inhibitors are still in different stages of clinical trials ([Table 2](#ijms-21-05164-t002){ref-type="table"}). Compared to Ibrutinib, Orelabrutinib has a better response rate and superior safety profile in a phase 2 study with relapsed or refractory MCL patients \[[@B54-ijms-21-05164]\]. Tirabrutinib was granted the orphan drug status and is now preregistered for lymphoma \[[@B55-ijms-21-05164]\]. Recently (Dec.2019) safety and efficacy data from a phase 2 study against CLL \[[@B56-ijms-21-05164]\] and long term safety study with this compound in MCL \[[@B57-ijms-21-05164]\] were disclosed. An oral, reversible covalent BTK inhibitor, Rilzabrutinib is currently in phase 3 for pemphigus. Meanwhile, orally active, brain-penetrant SAR-442168 recently \[[@B58-ijms-21-05164]\] met primary end point for phase 2 trials of relapsing multiple sclerosis (MS) and is entering phase 3 trial later this year in relapsing and progressive MS. ABBV-105 is going through phase 2 for RA and SLE, but for better clinical success, it is being explored in combination (renamed as ABBV-559) with JAK1 inhibitor (Upadacitinib) for the same disease ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

Dasatinib, a small molecule inhibitor of Bcr-abl tyrosine kinase and Src-Family kinase and later found to be a BTK inhibitor as well, was launched for CLL. It is in different stages for other cancers, but is discontinued for pancreatic cancer \[[@B59-ijms-21-05164]\] and scleroderma due to adverse events and reports of spontaneous pulmonary arterial hypertension \[[@B60-ijms-21-05164]\]. Similarly, EGFR inhibitors (Olafertinib and DZD-9008) were later found to inhibit BTK. BMS-986142 and Fenebrutinib by BMS and Genentech were taken to clinic for many indications, but the studies were terminated or completed without any significant outcome due to various reasons, respectively. Many other small molecule BTK inhibitors like CT-1530, BIIB-068, TAK-020 or GDC-0834 were also discontinued or no development was reported in phase 1 itself ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

ijms-21-05164-t002_Table 2

###### 

Clinical small molecule inhibitors of cellular receptors adaptor protein in NF-kB pathway.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                Originator/Developer                                                Stage                                  Indication                                                      Trail No.                               Other Information
  ------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------- --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Bruton's tyrosine kinase (BTK) inhibitors***                                                                                                                                                                                                                                        

  Zanubrutinib                                                        BeiGene                                                             Launched at 2019                       MCL                                                             NCT04002297                             BRUKINSA oral dose is 160 mg twice daily or 320 mg once daily.TEAE: Decreased neutrophil count, platelet count and hemoglobin \[[@B53-ijms-21-05164]\].Case reports of Hepatitis-B reactivation.

  Preregistration                                                     CLL                                                                 NCT03734016                                                                                                                                    

  Phase 3                                                             BCL, RRWM                                                           NCT03332173                                                                                                                                    

  Phase 2                                                             DLBCL, Follicular lymphoma, Lymphoma, CLL, Lymphosarcoma, FL, MZL   NCT03145064; NCT04282018                                                                                                                       

  Acalabrutinib                                                       AstraZeneca/Parexel                                                 Phase 3                                CLL                                                             NCT04008706                             Potentially serious TEAE: Severe bone marrow suppression, infections, bleeding, tumor lysis syndrome, and renal toxicity \[[@B61-ijms-21-05164]\].Report of Atrial-flutter in an off-label use.Herpes zoster infection and a case of Hepatitis-B reactivation observed.

  Acerta Pharma/AstraZeneca, Biologics Inc, Merck                     Launched 2017                                                       MCL                                    NCT02972840                                                                                             

  Acerta Pharma                                                       Phase 3                                                             CLL                                    NCT02970318                                                                                             

  Acerta Pharma/AstraZeneca                                           Phase 2                                                             COVID-19                               NCT04346199, NCT04380688                                                                                

  Phase 2                                                             Chronic GVHD                                                        NCT04198922                                                                                                                                    

  Acerta Pharma                                                       Phase 2                                                             WM                                     NCT02180724                                                                                             

  Phase 2                                                             Metastatic Pancreatic Cancer                                        NCT02570711                                                                                                                                    

  Phase 2                                                             RA                                                                  NCT02387762                                                                                                                                    

  Acerta Pharma BV\                                                   Phase 2                                                             Ovarian Cancer                         NCT02537444                                                                                             
  Merck Sharp & Dohme Corp.                                                                                                                                                                                                                                                              

  Phase 2                                                             NSCLC                                                               NCT02448303                                                                                                                                    

  Phase 2                                                             Squamous Cell Carcinoma of the Head and Neck                        NCT02454179                                                                                                                                    

  Acerta Pharma/Swedish Medical centre                                Phase 2                                                             DLBCL                                  NCT03736616                                                                                             

  Ibrutinib                                                           Janssen/Pharmacyclics; M.D. Anderson Cancer Center                  Launched 2013                          CLL                                                             NCT02801578                             420 mg orally once daily dose for CLL.Serious TEAE: hemorrhage, hypertension, ventricular arrhythmias, atrial fibrillation, atrial flutter, decrease in blood cell counts and Tumor lysis syndrome.Invasive fungal infections and Hepatitis-B reactivation observed.Ibrutinib-induced autoimmune hemolytic anemia and rare nail plate abnormalities also seen \[[@B62-ijms-21-05164]\].

  Launched 2013                                                       WM                                                                  NCT02165397                                                                                                                                    

  Launched 2013                                                       MCL                                                                 NCT01646021                                                                                                                                    

  Phase 2                                                             GVHD                                                                NCT02195869                                                                                                                                    

  Janssen/Pharmacyclics                                               Phase 3                                                             Metastatic Pancreatic Adenocarcinoma   NCT02436668                                                                                             

  Phase 3                                                             DLBCL                                                               NCT01855750                                                                                                                                    

  Phase 3                                                             RRCLL, SLL                                                          NCT01578707                                                                                                                                    

  Dasatinib                                                           BMS/Dana-Farber Cancer Institute                                    Launched 2006                          CML, acute cell lymphoblastic leukemia-lymphoma                 NCT00123487, NCT03020030                TEAE: Cytopenias, fluid retention, pleural effusion, dyspnea, gastrointestinal disorders, skin rash, headache and fatigue \[[@B63-ijms-21-05164]\].Low blood cell count, Pulmonary Arterial Hypertension and Tumor lysis syndrome also seen.Often requires dose interruption and/or dose reduction.

  BMS                                                                 Phase 3                                                             Prostatic Neoplasms                    NCT00744497                                                                                             

  BMS/NCI                                                             Phase 2                                                             DLBCL                                  NCT00608361                                                                                             

  Phase 2                                                             Rhabdomyosarcoma                                                    NCT0304170                                                                                                                                     

  BMS/OSI pharma/M.D. Anderson Cancer Center                          Phase 2                                                             NSCLC                                  NCT00826449                                                                                             

  BMS/Massachusetts General Hospital                                  Phase 2                                                             CLL                                    NCT00438854                                                                                             

  Phase 2                                                             Cholangiocarcinoma                                                  NCT02428855                                                                                                                                    

  BMS                                                                 Phase 2                                                             Breast Cancer                          NCT00767520                                                                                             

  BMS/Jorge J. Castillo, MD                                           Phase 2                                                             WM                                     NCT04115059                                                                                             

  Tirabrutinib                                                        Ono Pharmaceutical/Gilead Sciences                                  Registered                             Lymphoma                                                        NCT03162536                             TEAE: neutropenia, lymphopenia, leukopenia, and erythema multiforme \[[@B64-ijms-21-05164]\].Also observed pneumocystis jirovecii pneumonia and interstitial lung disease in a patient at highest dose of 480 mg QD.

  Ono Pharmaceutical/Gilead Sciences                                  Preregistration                                                     WM                                     NCT03740529                                                                                             

  Rilzabrutinib                                                       Principia Biopharma                                                 Phase 3                                Pemphigus vulgaris                                              NCT02704429                             Orphan drug status for Pemphigus vulgaris and Idiopathic thrombocytopenic purpura.

  Evobrutinib                                                         Merck Serono/EMD Serono                                             Phase 3                                MS                                                              NCT04032158                             TEAE: Nasopharyngitis and increases in levels of alanine aminotransferase, aspartate aminotransferase and lipase \[[@B65-ijms-21-05164]\].

  Merck Serono/EMD Serono                                             Phase 2                                                             RA                                     NCT02784106                                                                                             

  Orelabrutinib                                                       InnoCare Pharma/Beijing                                             Phase 2                                SLE                                                                                                     TEAE: thrombocytopenia and neutropenia \[[@B66-ijms-21-05164]\].Profile better than Ibrutinib.

  MZL                                                                                                                                                                                                                                                                                    

  ABBV-105                                                            AbbVie                                                              Phase 2                                SLE                                                             NCT03978520                             Focus is on ABBV-599 which is the ABBV-105/upadacitinib-combination

  RA                                                                  NCT03682705                                                                                                                                                                                                        

  ABBV-599                                                            AbbVie                                                              Phase 2                                RA, SLE                                                         NCT03682705, NCT03978520                

  SAR-442168                                                          Principia Biopharma/Sanofi                                          Phase 2                                Relapsing MS                                                    NCT03996291                             Common TEAE: Headache, upper respiratory tract infection and nasopharyngitis \[[@B67-ijms-21-05164]\].

  Branebrutinib                                                       BMS                                                                 Phase 2                                RA, SLE, Sjogren's syndrome                                     NCT04186871                             In phase 1, no serious TEAE observed \[[@B68-ijms-21-05164]\].

  TAS-5315                                                            Taiho Pharmaceutical                                                Phase 2                                RA                                                              NCT03605251                             Observed decrease in platelet aggregation and prolonged bleeding time in phase 1 \[[@B69-ijms-21-05164]\].

  Remibrutinib                                                        Novartis                                                            Phase 2                                Asthma, Sjogren's syndrome, Urticaria                           NCT03944707, NCT04035668, NCT04109313   Phase 2 trial in Urticaria suspended due to COVID-19.

  BMS-986142                                                          BMS                                                                 Phase 2                                RA                                                              NCT02638948                             TEAE: dizziness and nausea.Increase in Alanine aminotransferase \[[@B70-ijms-21-05164]\].

  Sjogren's syndrome                                                  NCT02843659                                                                                                                                                                                                        

  Fenebrutinib                                                        Genentech                                                           Phase 2                                Urticaria                                                       NCT03693625                             Higher doses may increase liver enzymes \[[@B71-ijms-21-05164]\].

  Poseltinib                                                          Hanmi Pharmaceutical/Eli Lilly                                      Phase 2                                RA                                                              NCT02628028                             Phase 2 discontinued as study failed to demonstrate its target effectiveness in the interim results \[[@B72-ijms-21-05164]\].

  Spebrutinib                                                         Celegene                                                            Phase 2                                RA                                                              NCT01975610                             Celgene acquired by Bristol-Myers Squibb.

  Phase 1                                                             CLL                                                                 NCT01732861                                                                                                                                    

  DTRMWXHS-12                                                         Zhejiang DTRM Biopharma                                             Phase 2                                DLBCL, R and RCLL, Follicular Lymphoma                          NCT04305444                             No development reported for B-cell lymphoma.

  Phase 1                                                             MCL                                                                 NCT03836768                                                                                                                                    

  Phase 1                                                             CLL, BCL                                                            NCT02891590                            Evaluate the safety, tolerability and PK profile.                                                       

  CT-1530                                                             Centaurus Biopharma Co., Ltd.                                       Phase 1/2                              B Cell-NHL, CLL, WM                                             NCT02981745                             Discontinued for all indications

  REDX08608                                                           Redx Pharma/Loxo oncology                                           Phase 1/2                              CLL/SLL or NHL                                                  NCT03740529                             In basal cell cancer, no development reported.

  M-7583                                                              EMD Serono                                                          Phase 1/2                              MCL, DLBCL, Relapsed/Refractory B Cell Malignancies             NCT02825836                             TEAE: Neutropenia, febrile neutropenia and pneumonia \[[@B73-ijms-21-05164]\].

  ARQ-531                                                             ArQule/Merck                                                        Phase 1/2                              Hematological malignancies                                      NCT03162536                             Well-tolerated through 65 mg QD \[[@B74-ijms-21-05164]\].

  Vecabrutinib                                                        Biogen Idec, Sunesis Pharmaceuticals                                Phase 1/2                              Hematological malignancies                                      NCT03037645                             TEAE: Anemia, headache and night sweats.

  TAK-020                                                             Takeda                                                              Phase 1                                RA                                                              NCT02413255                             TEAE; Abdominal distension, upper abdominal pain, nausea, and headache

  BIIB068                                                             Biogen                                                              Phase 1                                SLE                                                             NCT02829541                             No update beyond phase 1

  AC-0058TA                                                           ACEA Biosciences                                                    Phase 1                                SLE                                                             NCT03878303                             Phase 1 for Autoimmune disorders completed in 2017 and no further progress reported.

  SN-1011                                                             Sinomab                                                             Phase 1                                Autoimmune disorder                                             NCT04041544                             

  BIIB-091                                                            Biogen                                                              Phase 1                                Healthy Volunteer (MS)                                          NCT03943056                             Completes phase 1 trial for Multiple sclerosis.

  TG-1701                                                             Eternity Bioscience/TG Therapeutics                                 Phase 1                                Healthy Volunteer (NHL, CLL)                                    NCT04291846                             Encouraging safety profile.

  CG-806                                                              CrystalGenomics, Aptose Biosciences                                 Phase 1                                CLL, SLL, NHL                                                   NCT03893682                             No drug-related dose-limiting toxicities.

  ***Interleukin-1 receptor-associated kinase (IRAK) inhibitors***                                                                                                                                                                                                                       

  PF-06650833                                                         Pfizer                                                              Phase 2                                RA                                                              NCT02996500                             TEAE: Infections and infestations \[[@B75-ijms-21-05164]\].

  CA-4948                                                             Curis Pharmaceuticals                                               Phase 1                                AML, MDS                                                        NCT04278768                             Adverse events: amylase/lipase increased neutrophil count decreased, rash and rhabdomyolysis \[[@B76-ijms-21-05164]\].

  Hematological malignancies                                          NCT03328078                                                                                                                                                                                                        

  R-835                                                               Rigel Pharmaceuticals                                               Phase 1                                Autoimmune and Inflammatory Diseases                                                                    Rigel initiates phase 1 clinical trial \[[@B77-ijms-21-05164]\].

  BAY-1834845                                                         Bayer                                                               Phase 1                                Pelvic Inflammatory Disease                                     NCT03054402                             No update beyond phase 1 for Pelvic Inflammatory Disease

  Inflammation                                                        NCT03244462                                                                                                                                                                                                        

  Psoriasis                                                           NCT03493269                                                                                                                                                                                                        

  BAY-1830839                                                         Bayer                                                               Phase 1                                RA                                                              NCT03540615                             

  Health volunteers (For RA)                                          NCT03965728                                                                                                                                                                                                        

  ***Cellular Inhibitor of Apoptosis Proteins (c-IAP) inhibitors***                                                                                                                                                                                                                      

  Birinapant (TL32711)                                                Jonsson Comprehensive Cancer Center, NCI                            Phase 2                                High Grade Ovarian, Fallopian Tube, Primary Peritoneal Cancer   NCT02756130                             Birinapant and pembrolizumab combination had futile outcome in patients with MSS colorectal cancer \[[@B78-ijms-21-05164]\].

  TetraLogic Pharmaceuticals                                          Phase 1                                                             Hepatitis B                            NCT02288208                                                                                             

  APG-1387 (SM-1387)                                                  Ascentage Pharma                                                    Phase 2                                Advanced Solid Tumors                                           NCT04284488                             TEAE: Elevated bilirubin, lipase increase and shortness of breath \[[@B79-ijms-21-05164]\].Exploring for Hepatitis B in both Treatment-experienced and naïve patient.

  Phase 2                                                             Myelofibrosis                                                       NCT04354727                                                                                                                                    

  Phase 1                                                             Advanced Solid Tumors or Hematologic Malignancies                   NCT03386526                                                                                                                                    

  Ascentage Pharma, HealthQuest Pharma                                Phase 1                                                             Chronic Hepatitis B                    NCT03585322                                                                                             

  LCL-161                                                             Mayo Clinic                                                         Phase 2                                RR Plasma Cell Myeloma                                          NCT01955434                             Hematologic toxicities: thrombocytopenia and anemia \[[@B80-ijms-21-05164]\].Completed phase I trial in multiple myeloma.No development reported for pancreatic cancer and solid tumors.

  MD Anderson Cancer Center, NCI, Novartis                            Phase 2                                                             Myelofibrosis                          NCT02098161                                                                                             

  Novartis Pharmaceuticals                                            Phase 2                                                             Breast Cancer                          NCT01617668                                                                                             

  Phase 2                                                             Small Cell Lung Cancer\                                             NCT02649673                                                                                                                                    
                                                                      Ovarian Cancer                                                                                                                                                                                                     

  US Oncology Research\                                               Phase 1                                                             Metastatic Pancreatic Cancer           NCT01934634                                                                                             
  Novartis, Delta Clinical Research, LLC                                                                                                                                                                                                                                                 

  Novartis Pharmaceuticals                                            Phase 1                                                             Neoplasms                              NCT01968915                                                                                             

  Phase 1                                                             Solid Tumors                                                        NCT01240655                                                                                                                                    

  Phase 1                                                             Advanced Solid Tumors                                               NCT01098838                                                                                                                                    

  Phase 1                                                             MM                                                                  NCT03111992                                                                                                                                    

  ASTX660                                                             Astex Pharmaceuticals                                               Phase 1                                AML                                                             NCT04155580                             Common TEAE: Anemia, increased lipase and lymphopenia \[[@B81-ijms-21-05164]\].

  Debio 1143 (AT-406)                                                 Debiopharm                                                          Phase 1                                Advanced Solid Tumors and Lymphomas                             NCT01078649                             TEAE: Mucositis, dysphagia and anemia \[[@B82-ijms-21-05164]\].

  CUDC-427                                                            Curis Pharmaceuticals                                               Phase 1                                Lymphoma                                                        NCT01908413                             Few patients discontinued and TEAE includes pruritus and fatigue \[[@B83-ijms-21-05164]\].
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AML---acute myeloid leukemia; BCL----B-cell leukemia; BMS---Bristol-Myers Squibb; CLL---chronic lymphocytic leukemia; CML---chronic myeloid leukemia; CMML---chronic myelomonocytic leukemia; DLBCL---diffuse large B-cell lymphoma; GVHD---graft versus host disease; HCC---hepatocellular Carcinoma; MCL---Mantle cell lymphoma; MDS---Myelodysplastic Syndrome; MM---Multiple myeloma; MS---multiple sclerosis; MZL---marginal zone lymphoma; NHL---Non-Hodgkin lymphoma; NSCLC---non-small cell lung cancer; RA---rheumatoid arthritis; RRCLL---relapsed and refractory chronic lymphocytic leukemia; RRMM---relapsed and refractory Multiple myeloma; SLL---small lymphocytic lymphoma; SLE---systemic lupus erythematosus; TCL---T-Cell Lymphoma; TEAE---Treatment-emergent adverse effects; WM---Waldenstrom macroglobulinemia.

### 2.2.2. Interleukin-1 Receptor-associated Kinase (IRAK) {#sec2dot2dot2-ijms-21-05164}

IRAK is the downstream target of TLR and IL1R and the activation of these receptors initiate signaling cascade through MYD88 adaptor protein. This signaling subsequently involving IRAK and IKK complex, leads to NF-κB mediated transcription of certain genes that are involved in various inflammation condition. Quite often, components of this pathway are found to be genetically altered, resulting in specific human cancers \[[@B84-ijms-21-05164]\]. The central role of IRAK in these signaling pathways makes them an attractive target for treating diseases with MYD88 gene mutations as observed in B-cell malignancies \[[@B84-ijms-21-05164]\] and certain inflammatory diseases \[[@B85-ijms-21-05164]\] ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

The most advanced IRAK small molecule inhibitor, Pacritinib, which primarily targets Janus Kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3), also inhibits IRAK1 \[[@B86-ijms-21-05164]\]. In 2019, dual IRAK1/4 inhibitor, R-835, successfully completed phase 1 study for autoimmune disorder. Among selective IRAK4 reversible inhibitors, PF-06650833, which is currently at phase 2 for RA and hidradenitis suppurativa, is the front runner and has favorable safety and pharmacokinetic profile from a phase 1 study \[[@B75-ijms-21-05164]\]. Orally active CA-4948 (AU-4948) that was out-licensed to Curis by Aurigene, is currently in phase 1 for acute myeloid leukemia (AML), Myelodysplastic syndromes and non-Hodgkin lymphoma (NHL) \[[@B87-ijms-21-05164]\]. Though, it also inhibits FLT3, it is being showcased as an IRAK4 inhibitor. BAY-1834845 was considered for pelvic inflammatory disorders, psoriasis and RA, but there is no update since the phase 1 trial, which was completed in 2018. BAY-1830839 for RA completed its phase 1 study with increasing single oral doses mid of last year. There were investigations also conducted for safety, tolerability, and pharmacokinetics during increasing repeated oral doses and potential drug-drug interactions with midazolam and methotrexate ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

### 2.2.3. Phosphatidyl Inositol-3 Kinases (PI3K)/AKT {#sec2dot2dot3-ijms-21-05164}

PI3K, a lipid kinase, mediates signaling from growth factors, cytokines, TLRs, TCR, BCR, and cell stress. The PI3K mediated signaling activates one of its signaling cascades involving the NF-κB pathway through direct activation of IKK via phosphorylation of IKKα \[[@B88-ijms-21-05164]\] and also through AKT (also known as protein kinase B) phosphorylation eventually leading to NF-κB signaling \[[@B89-ijms-21-05164],[@B90-ijms-21-05164]\]. PI3K comprises of one catalytic p110 subunit and two regulatory p85 and p55 subunits. Based on different structures and specific substrates of PI3K, it is divided into three classes called Class I, II, and III PI3Ks and of these Class I are majorly explored. Class I PI3Ks classified as class IA and class IB further Class1A consists three isoforms PI3Kα, PI3Kβ, and PI3Kδ and their catalytic subunits are p110α, p110β, and p110δ, respectively, while p110γ catalytic subunit represents class IB. PI3K P110α is strongly correlated with angiogenesis, while p110β, δ, and γ contribute to inflammatory responses \[[@B91-ijms-21-05164],[@B92-ijms-21-05164],[@B93-ijms-21-05164]\].

At basal conditions, the p110 catalytic subunit gets stabilization by forming a heterodimer with regulatory p85 subunit \[[@B94-ijms-21-05164],[@B95-ijms-21-05164]\]. Upon stimulation, phosphorylation p85 regulatory subunit of PI3K leads to the activation of the p110 catalytic subunit. The activated PI3K heterodimer (viz. p110α and p85) induce the conversion of phosphatidylinositol 4,5 bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3, a second messenger binds to downstream targets and leads into its signaling cascades involving NF-κB pathways through direct activation of IKK via phosphorylation of IKK or through AKT phosphorylation and subsequent activation of p65 through IKK complex \[[@B89-ijms-21-05164],[@B90-ijms-21-05164],[@B95-ijms-21-05164],[@B96-ijms-21-05164]\].

Inhibition of PI3K or any downstream target like AKT will effectively modulate the signaling cascade including activation and NF-κB-dependent gene expression. Many PI3K and AKT inhibitors have been taken into clinical trials for a multitude of diseases and are extensively reviewed in the literature \[[@B95-ijms-21-05164],[@B97-ijms-21-05164],[@B98-ijms-21-05164]\]. Some of the PI3K inhibitors are even approved for different indications. Many of them are designed to be active against the specific isoform like Idelalisib and Alpelisib, predominantly active against PI3Kα isoform and thus may have reduced ADR. On the other hand, for better efficacy profile, Copanlisib blocks both PI3Kα and PI3Kδ isoforms and Duvelisib specifically inhibits the Class1A PI3Kδ and Class1B PI3K. To date, no AKT inhibitor has been approved in the market but many are in clinical trials \[[@B92-ijms-21-05164],[@B95-ijms-21-05164]\].

### 2.2.4. Cellular Inhibitor of Apoptosis Proteins (c-IAP) {#sec2dot2dot4-ijms-21-05164}

IAPs comprise of a family of eight member proteins that are well known for their ability to prevent apoptosis through inhibiting caspase activation or activity. Their role as anti-apoptotic proteins and their dysregulation, either by overexpression or loss of endogenous antagonists, is associated with tumor growth, poor prognosis, and resistance to treatment, making them attractive targets \[[@B99-ijms-21-05164]\]. Recent discoveries have shown that cIAP1, cIAP2, and X-linked IAP (XIAP) also regulate signaling pathways of the innate immune system by ubiquitylating their substrates. Moreover, cIAP1 and cIAP2 inhibit the TNF receptor mediated apoptosis through blocking the caspase-8 activation by TRAF2 interaction \[[@B100-ijms-21-05164]\].

In TNF-α induced inflammatory pathway, cIAP1/2 plays a vital role in NF-κB activation. Binding of TNF-α to TNFR recruits TNFR-associated death domain protein (TRADD), receptor-interacting protein kinase 1 (RIPK1), TRAF2, and cIAP1/2 to form complex for NF-κB signaling \[[@B101-ijms-21-05164]\]. IAPs have a carboxy-terminal RING (really interesting new gene) domain which allows them to act as ubiquitin E3 ligases that facilitate to conjugate themselves and with associated proteins such as RIPK1 through K11, K48, and K63-linked ubiquitin chains. This ubiquitin chain facilitates the docking of TAB2/3/TAK1 and the IKK subunit NF-κB essential modulator (NEMO), eventually leading to NF-κB dependent and mitogen-activated protein kinase (MAPK) dependent inflammation, proliferation, and cell survival \[[@B102-ijms-21-05164]\]. Apart from inhibiting caspase activation, ubiquitin E3 ligases property of cIAP1/2 encouraged the researcher to explore cIAP1/2 in an immune and inflammatory target \[[@B100-ijms-21-05164],[@B101-ijms-21-05164],[@B103-ijms-21-05164],[@B104-ijms-21-05164]\].

ASTX660, a non-peptidomimetic small molecule antagonist of cIAP1/2 and XIAP (X-linked inhibitor of apoptosis protein), is in phase 1/2 study for advanced solid tumors and lymphomas and phase 2 study for Peripheral and Cutaneous T-Cell Lymphoma (TCL) \[[@B105-ijms-21-05164]\] ([Table 2](#ijms-21-05164-t002){ref-type="table"}). Second mitochondria-derived activator of caspase (SMAC) mimetic, AT406 (Debio-1143), the small molecule IAP antagonist, based on clinically compelling phase 2 results (by Debiopharm) recently (February 2020) got breakthrough therapy status in head and neck cancer \[[@B82-ijms-21-05164]\]. AT406 also achieved orphan drug status for Ovarian cancer \[[@B106-ijms-21-05164]\] and is in phase 2 for solid tumor. Another SMAC mimetic, APG-1387, inhibits cIAP1/2 and XIAP and got approved in February 2020 for phase 1b/2 trial in China for solid tumors \[[@B107-ijms-21-05164]\]. LCL-161 didn't progress beyond phase 2 trials for breast cancer, multiple myeloma (MM) and myelofibrosis but a recently concluded phase 1 combination study for MM (<https://clinicaltrials.gov/ct2/show/NCT03111992>) suggest that Novartis is still interested in this molecule. Meanwhile, combination studies of Birinapant (SMAC mimetic) with Keytruda for MSS- CRC (Phase 2) and Entevir/Tenofovir for viral hepatitis B (Phase 1) were terminated due to futility analysis of data \[[@B78-ijms-21-05164]\] and cranial nerve palsies \[[@B108-ijms-21-05164]\], respectively ([Table 2](#ijms-21-05164-t002){ref-type="table"}).

3. Inhibition on IKK Complex in NF-κB Pathway {#sec3-ijms-21-05164}
=============================================

3.1. IKKα and IKKβ Inhibitors {#sec3dot1-ijms-21-05164}
-----------------------------

During the stimulation of the canonical NF-κB pathway, IKK complex, made of IKKα and IKKβ as kinase subunit and IKKγ as regulatory subunit, is activated \[[@B109-ijms-21-05164]\]. Activation of the IKK complex plays a central role in the canonical NF-κB pathway. The signaling cascade begins through the activation of receptors such as IL1R, TNFR, TLR, TCR and BCR at the cell membrane level. Once activated, these receptors and their associated protein complexes come together and percolate into intracellular signaling networks by utilizing adaptor protein interactions, protein phosphorylation, non-degradative ubiquitination and other signal-transducing mechanisms to activate this pathway. Evidence shows that diverse signaling cascades from various cellular receptors converge to activate TAK1, which then phosphorylates IKKβ at T-loop serine residues, S177 and S181, resulting in the activation of the IKK complex. IKK complex eventually phosphorylates IκB leading to p65:p50 release \[[@B33-ijms-21-05164],[@B110-ijms-21-05164],[@B111-ijms-21-05164]\]. For the non-canonical pathway IKKα plays an indispensable role. Once TNFRSF receptor (RANK, BAFFR (B-cell activating factor receptor), CD40, TWEAK (Tumor necrosis factor-like weak inducer of apoptosis), and LTβ) is activated in the non-canonical NF-κB pathway, NIK levels are stabilized. NIK phosphorylates IKKα homodimer on T-loop serine residues, S176 and S180. This activates IKKα complex and leads to P100 processing to p52 through partial ubiquitination \[[@B14-ijms-21-05164],[@B112-ijms-21-05164]\]. Thus, IKKα and IKKβ play a critical role in the NF-κB pathway and their inhibitors would effectively block the whole pathway. It is for the same reason that no IKKα or IKKβ inhibitor has cleared phase 2 studies \[[@B21-ijms-21-05164]\] ([Table 3](#ijms-21-05164-t003){ref-type="table"}). SAR-113945, an IKKα/β small molecule inhibitor developed by Sanofi and MLN-0415 by Millennium Pharmaceuticals did not meet primary endpoints of phase 2 and safety profile of phase 1, respectively. Also, Merck's AS-602868 and Leo Pharma's CHS-828 were also discontinued due to unknown reason ([Table 3](#ijms-21-05164-t003){ref-type="table"}). Prescott et. al. \[[@B109-ijms-21-05164]\] has discussed these failures and reasoned that the development of more selective non-ATP competitive inhibitors, usage of isoform-specific readouts to differentiate role of IKKα vs. IKKβ in cellular activity and appropriate application of therapeutics should lead to more clinical success.

Sulfasalazine, a disease-modifying anti-rheumatic drug (DMARD) launched for RA and other autoimmune disorders, was also reported to directly inhibit IKKα and IKKβ by antagonizing ATP binding \[[@B113-ijms-21-05164]\]. Anti-inflammatory and immunosuppressive effects of Sulfasalazine are attributed to the suppression of NF-κB activation via inhibition of IKKs. Many nonsteroidal anti-inflammatory drugs (NSAID) like Aspirin and Salicylate are inhibitors of NF-κB pathway \[[@B114-ijms-21-05164]\]. They inhibit ATP binding to IKKβ and thus prevent activation & translocation of NF-κB to the nucleus. Salsalate, the pro-drug of salicylate, is marketed for inflammatory and non-inflammatory disorders. Moreover, in diabetes, since the NF-κB pathway serves as a potential target, clinical trials to test for the efficacy of salsalate in reducing glycemia and insulin resistance diabetes were undertaken successfully \[[@B115-ijms-21-05164]\].

3.2. Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Gamma (IKKγ) Inhibitors {#sec3dot2-ijms-21-05164}
-------------------------------------------------------------------------------

IKKγ, also known as NF-κB essential modulator (NEMO), is the regulatory subunit of the IKK complex. Its inhibition or inhibition of its binding to the complex renders IKK inactive. Unlike inhibition of IKKα or IKKβ that results in gross toxicity, inhibition of IKKγ only affects the NF-κB pathway mediated by IKK complex and will not inhibit the standalone activities of IKKα or IKKβ or the non-canonical pathway. NEMO Binding Domain (NBD) peptide was developed to inhibit binding of NEMO to IKKα or IKKβ and reportedly inhibits only the inflammation induced NF-κB activation pathway, with little or no effect on the basal NF-κB activity \[[@B21-ijms-21-05164],[@B116-ijms-21-05164]\]. Unfortunately, due to the low plasma stability and druggability issues of this peptide, it was never taken to clinic. Even modifications of NBD \[[@B117-ijms-21-05164]\] such as covalently linking it to either cell penetrating peptides or Drosophila Antennapedia domain or even macrocyclization to make it into a proteolytically stable bicyclic peptide could not take any NEMO inhibitor to clinical trials. To succeed, IKKγ inhibitors have to overcome the proteasomal degradation and address drug delivery issues.

3.3. IKKε and Tank Binding Kinase 1 (TBK1) Inhibitors {#sec3dot3-ijms-21-05164}
-----------------------------------------------------

IKKε share 67% sequence identity with TBK1 and collectively regulates activation of interferon regulatory factor (IRF)-family factors (IRF3/5/7) by Rig-I like receptors and other receptors \[[@B118-ijms-21-05164]\]. Phosphorylation of IRF3 has subsequently led to expression of interferon-stimulated genes (ISGs). TBK1 also phosphorylates STING (stimulator of interferon genes) and makes it more accessible for binding to IRF3. To date, no molecule that was specifically designed to inhibit IKKε or TBK1 has reached clinic trials. However, a number of small molecules that have been approved or explored for different mechanism of actions, were later found to inhibit IKKε/TBK1 \[[@B119-ijms-21-05164]\]. Amlexanox (Histamine and Leukotriene inhibitors---approved for Asthma), BX-795 (three phosphoinositide dependent protein kinase 1 inhibitors), Momelotinib (JAK inhibitor) are some of the examples. These compounds led to specific inhibitors like MPI-0485520 (developed by Myrexis) and DMXD-011 (by Domainex) but they were not taken beyond preclinical studies. Preclinical research for their use as a synthetic lethal target and their combination therapy are being explored and we may see more molecules in clinical trial.

ijms-21-05164-t003_Table 3

###### 

Clinical small molecules inhibitors targeting IKK complex in NF-κB pathway.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                     Originator/\                                         Stage                                   Indication                      Trail No.      Other Information
                                           Developer                                                                                                                                   
  ---------------------------------------- ---------------------------------------------------- --------------------------------------- ------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***IKK α/β Inhibitors***                                                                                                                                                             

  CHS-828                                  Leo Pharma                                           Discontinued at phase 2                 Solid tumor                     NCT00003979    Originally Nicotinamide phosphoribosyl transferase (NAMPT) inhibitor.Dose-limiting toxicities; thrombosis, thrombocytopenia, esophagitis, diarrhea, and constipation \[[@B120-ijms-21-05164]\].

  IMD-1041\                                Institute of Medicinal Molecular Design              Phase 2                                 COPD                            NCT00883584    No further development reported for COPD.Clinical phases for other indication unknown.
  (Pro-drug of IMD-0354)                                                                                                                                                               

  NA                                       Age-related macular degeneration, DM, Glaucoma, PF   NA                                                                                     

  SAR-113945                               Sanofi                                               Discontinued at Phase 2                 OA                              NCT01598415    SAR-113945 gave as intra-articular injection.Phase 1 studies was promising but Phase 2b proof-of-concept study failed to show efficacy in a larger patient sample size \[[@B121-ijms-21-05164]\].

  Discontinued at Phase 1                  OA                                                   NCT01113333, NCT01463488, NCT01511549                                                  

  MLN-0415                                 Millennium Pharmaceuticals                           Discontinued at Phase 1                 Arthritis, Inflammation, MS     NA             Unfavorable safety profile in Phase 1.

  VGX-1027                                 VGX Pharmaceuticals                                  Phase 1                                 Healthy subjects (RA)           NCT00627120    No development reported for RA or other diseases.

  Phase 1                                  Healthy subjects (RA)                                NCT00760396                                                                            

  Teglarinad Chloride (EB-1627; GMX1777)   Leo Pharma                                           Phase 1                                 Malignant melanoma              NCT00724841,   Multi dose study conducted with combination of Temozolomide.

  Phase 1                                  Lymphoma, Solid tumors                               NCT00457574                             Single therapy was performed.                  

  AS-602868                                Merck                                                Discontinued at Phase 1                 Hematological malignancies      NA             Also, inhibit FLT3.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: COPD---chronic obstructive pulmonary disease; DM---Diabetes mellitus; FLT3---FMS-like tyrosine kinase 3; MS---Multiple sclerosis; NA---not available; OA---osteoarthritis; PF---Pulmonary fibrosis; RA---rheumatoid arthritis.

3.4. NF-κB Inducing Kinase (NIK) Inhibitors {#sec3dot4-ijms-21-05164}
-------------------------------------------

NIK is the master regulator of non-canonical NF-κB pathway \[[@B18-ijms-21-05164]\]. It phosphorylates IKKα and that subsequently initiates p100--p52 processing. Mature p52 heterodimerizes with RelB and translocate to the nucleus to regulate gene transcription. Stabilization of NIK and its accumulation is a hallmark in many cancers. Further, the relevance of the non-canonical NFKB pathway in B-cell maturation makes NIK a very desirable target. Many research groups, including pharmaceutical companies like Amgen, Genentech published multiple patents with subnanomolar enzymatic activity and even appreciable in vivo efficacy. However, none of them made it to clinical trials. The closest one was Tracon pharmaceutical's TRC-694 (JNJ-64290694 in-licensed from Janssen) that they were planning to take into phase 1 proof-of-concept study for patients with hematologic malignancies, including myeloma. Last year they returned the rights to Janssen after completion of the pre-clinical study and no further development were reported \[[@B122-ijms-21-05164]\]. Most scaffolds, for potent NIK inhibition have an alkyne side chain that may be associated with some toxicity, but structurally different compounds published \[[@B123-ijms-21-05164]\] by Johnson not being considered for clinical trial negate this theory. The probable biology of NIK and its exact role in disease are still grey areas and appropriate indication or relevant combination needs to be worked out for clinical consideration.

4. Molecules that Inhibit Ubiquitin-Proteasome System (UPS) {#sec4-ijms-21-05164}
===========================================================

The relationship between protein homeostasis and proteolysis plays a key role for regulation of many pathways including NF-κB pathway. UPS is one of the main mechanisms \[[@B124-ijms-21-05164]\] of intracellular protein degradation that is also important for activating protein by partial degradation or post-translational modification. Proteolysis is highly controlled \[[@B125-ijms-21-05164]\] by multiple steps, both at the proteasome end and the targeted protein for degradation, to avoid non-specific degradation. It involves diverse enzymes that render further specificity to the proteolytic degradation. Some proteins need not be ubiquitinated before degradation like conversion of p105 to p50 in canonical NF-κB pathway or in post-translational processing. Similarly, some proteins also undergo nondestructive polyubiquitination in the signaling cascade.

In UPS, covalent attachment of multiple ubiquitin molecules with substrate proteins are intended for proteasomal degradation, which gives a recognition signal for the 26S proteasome. The two distinct and successive steps are involved in the degradation of protein substrates in this pathway, the first one is the ubiquitin conjugation cascade and the second one is destruction process mediated by proteasome core. The former one encompasses the enzymes required for activation, conjugation, and ligation of ubiquitin to protein substrates and the later one takes ubiquitinated proteins to their final fate. Ubiquitination happens typically with three sets of enzymes such as ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2), and ubiquitin ligases (E3) \[[@B126-ijms-21-05164],[@B127-ijms-21-05164]\].

In the first step, E1 activates this cascade through adenylation of the ubiquitin at the terminal carboxyl group of Glycine involves the hydrolysis of ATP to PPi. Eventually, E1 covalently links to ubiquitin via a high-energy thioester linkage. As a second activity, the activated ubiquitin is transferred from E1 to conjugating enzyme E2. On the final step, typically ubiquitin to the protein substrate requires E3 or ligase via forming an amide isopeptide bond between the carboxyl group of Glycine of ubiquitin and amino group of the protein substrate's internal Lys residue. After the mono-ubiquitination, subsequent ubiquitination conjugation cascade happens between glycine residue of ubiquitin and lysine residue of ubiquitin that is already conjugated to the protein substrate called as poly-ubiquitination \[[@B128-ijms-21-05164]\].

Protein substrate modification in UPS comprises two types of ubiquitin chains, single linkage types are called homotypic chains (mono and polyubiquitylation), where heterotypic chains comprise mixed linkages within the same polymer or one ubiquitin molecule has two or more ubiquitylated sites (mixed and branched ubiquitylation). Proteins can be modified at one lysine residue with either a single ubiquitin molecule or ubiquitin polymers called mono and polyubiquitylation respectively, multiple lysine residues modified with a single ubiquitin known as multiple mono ubiquitylation \[[@B126-ijms-21-05164],[@B129-ijms-21-05164]\].

Heterotypic chains are classified into mixed chains or branched chains. In mixed chains, each ubiquitin is modified only once by another ubiquitin, wherein branched chains, each ubiquitin can be modified by two or more ubiquitin molecules. Due to the huge number of possible conjugate combinations in branched chains, it is affecting different signaling pathways and K48/K63 is one of the most studied branched chains, implicated in NF-κB signaling and apoptosis \[[@B128-ijms-21-05164],[@B129-ijms-21-05164],[@B130-ijms-21-05164]\].

4.1. Proteasome Inhibitors {#sec4dot1-ijms-21-05164}
--------------------------

In the canonical and non-canonical NF-κB pathways, proteolytic degradation modulates multiple steps \[[@B125-ijms-21-05164]\]. In the canonical pathway, proteasomal degradation of IκB leads to release of active NF-κB complex (p50/RelA). In the non-canonical pathway, NIK/IKKα mediated phosphorylation of p100 converts it into p52 through partial proteolysis. Thus, these can be targeted for therapeutic intervention and proteasome inhibitors can be used to effectively modulate the NF-κB pathway ([Table 4](#ijms-21-05164-t004){ref-type="table"}). On the other hand, the critical role played by the proteasomes in fundamental cellular processes, may also lead to target related ADR.

The first clinically approved small molecule proteasome inhibitor, Bortezomib with boronic acid functionality, is a slow reversible inhibitor of the 20S proteasome \[[@B131-ijms-21-05164]\]. It is currently marketed for MCL, MM, and WM and registered for B-cell lymphoma (BCL). It is undergoing phase 3 for DLBCL and relapsed, or relapsed and refractory multiple myeloma (RRMM) ([Table 4](#ijms-21-05164-t004){ref-type="table"}) \[[@B132-ijms-21-05164]\]. The poor tissue penetration and high plasma clearance made it a poor choice for treating solid tumors \[[@B133-ijms-21-05164]\]. Development of resistance and peripheral neuropathy are serious limitations of this first-in-class drug \[[@B131-ijms-21-05164]\]. Ixazomib, a boronic ester pro-drug, was the first orally administered drug \[[@B134-ijms-21-05164]\] approved by the FDA in 2015. Though it is also a reversible inhibitor, unlike Bortezomib, it had fast disassociation rate when bound to RBC and had better tissue distribution. It was developed by Takeda and received orphan drug status for MM and amyloidosis ([Table 4](#ijms-21-05164-t004){ref-type="table"}). Ixazomib was approved in combination with lenalidomide and dexamethasone for RRMM \[[@B135-ijms-21-05164]\]. Last year, phase 3 trial of combination with dexamethasone was discontinued, as it did not demonstrate significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain amyloidosis \[[@B136-ijms-21-05164]\]. It was also discontinued for solid tumors ([Table 4](#ijms-21-05164-t004){ref-type="table"}).

The second generation Carfilzomib has an epoxyketone group, making it an irreversible inhibitor of 20S proteasome. It has received orphan drug status for MM and WM. The FDA approved it in 2012 for MM patients who has already received other therapies ([Table 4](#ijms-21-05164-t004){ref-type="table"}) \[[@B137-ijms-21-05164]\]. Amgen recently also completed phase 2 trial for MM as second-line or greater combination therapy with dexamethasone. Unlike bortezomib, patients using carfilzomib had less severe peripheral neuropathy \[[@B137-ijms-21-05164]\], but showed varying degree of adverse cardiovascular events \[[@B138-ijms-21-05164]\], due to its effects on myocardial proteasomes ([Table 4](#ijms-21-05164-t004){ref-type="table"}). There were reports \[[@B137-ijms-21-05164],[@B139-ijms-21-05164]\] of severe acute kidney injury and rhabdomyolysis in patients with additional complication. To overcome intravenous administration of Carfilzomib, orally bioavailable Oprozomib was developed. Oprozomib received orphan drug status for MM and WM \[[@B140-ijms-21-05164]\] ([Table 4](#ijms-21-05164-t004){ref-type="table"}). Last year Amgen and Onyx Pharmaceuticals completed phase 1b/2 trial for MM and hematological malignancies respectively. Earlier, Amgen reported phase 1b/2 combination study with melphalan and prednisone in transplant ineligible patients with newly diagnosed MM \[[@B140-ijms-21-05164]\].

Marizomib is a naturally occurring broad-spectrum proteasome inhibitor isolated from the marine actinomycetes *Salinispora tropica* a cytotoxic constituent called salinosporamide A. It is reported to be less toxic, more efficient and structurally different from other approved proteasome inhibitors ([Table 4](#ijms-21-05164-t004){ref-type="table"}) \[[@B141-ijms-21-05164]\]. Celgene explored this for the treatment of RRMM and demonstrated clinically relevant activity, good tolerability with no severe peripheral neuropathy or hematologic toxicity in phase 1 trial. Phase 2 trial for RRMM was also encouraging and as it can pass through the blood--brain barrier. This initiated phase 3 for the potential treatment for glioblastoma in combination with temozolomide-based radiochemotherapy \[[@B142-ijms-21-05164]\]. Disulfiram, launched in 1951 to support the treatment of chronic alcoholism, showed anticancer activity, possibly due to the disruption of the NF-κB pathway by proteasomal inhibition \[[@B143-ijms-21-05164],[@B144-ijms-21-05164]\]. It received orphan drug status for glioblastoma and is currently in phase 2 trials for pancreatic cancer as a second-line of therapy ([Table 4](#ijms-21-05164-t004){ref-type="table"}).

ijms-21-05164-t004_Table 4

###### 

Clinical small molecules inhibitors targeting Ubiquitin-Proteasome System (UPS) in NF-κB pathway.

  Drug                                                                        Originator/Developer                                                Stage                                                     Indication                            Trail No.                               Purpose/Other Information
  --------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Proteasome Inhibitors***                                                                                                                                                                                                                                                             
  Disulfiram                                                                  National Institute for Health and Welfare, Finland                  Launched 1951                                             Alcohol dependence                    NCT00435435                             Acetaldehyde dehydrogenase InhibitorInvestigated disulfiram and copper-supplement as add-on treatment.Got orphan drug status for Glioblastoma.Addition of disulfiram to chemotherapy in NSCLC led to 30% decrease in the sum of the longest diameter of target lesion.Common side effect: Bad taste in mouth, headache, nausea, drowsiness.May show hypophosphatemia cases of hepatitis, optic and peripheral neuritis \[[@B145-ijms-21-05164]\].
  Sahlgrenska University Hospital, Sweden                                     Phase 3                                                             Recurrent Glioblastoma                                    NCT02678975                                                                   
  Phase 3                                                                     Lung Cancer                                                         NCT00312819                                                                                                                             
  University of Utah                                                          Phase 2                                                             refractory disseminated malignant melanoma                NCT02101008                                                                   
  National Cancer Institute (NCI), Slovakia                                   Phase 2                                                             HER2 negative breast cancer                               NCT04265274                                                                   
  NCI, Slovakia                                                               Phase 2                                                             Germ Cell Tumor                                           NCT03950830                                                                   
  Mayo Clinic; NCI                                                            Phase 1                                                             Metastatic Pancreatic Cancer                              NCT02671890                                                                   
  Bortezomib                                                                  Millennium/Takeda Pharmaceuticals                                   Launched 2003                                             MCL, MM, WM                           NCT00722137, NCT00257114, NCT02844322   First clinically approved proteasome inhibitor, called VELCADE.Peripheral neuropathy is the common dose limiting toxicity.Thrombocytopenia observed but able to cure by platelet transfusions \[[@B146-ijms-21-05164]\].Other common issues are gastrointestinal disturbances and fatigue \[[@B132-ijms-21-05164]\].
  The Rogosin Institute                                                       Phase 4                                                             Chronic Kidney Disease and IgA Nephropathy                NCT01103778                                                                   
  Melanoma Institute Australia                                                Phase 4                                                             Melanoma                                                  NCT02645149                                                                   
  Janssen Research & Development, LLC                                         Phase 3                                                             Amyloidosis                                               NCT03201965                                                                   
  University Hospital Southampton NHS Foundation Trust; Janssen-Cilag Ltd.    Phase 3                                                             DLBCL                                                     NCT01324596                                                                   
  Millennium/Takeda Pharmaceuticals                                           Phase 3                                                             Relapsed or Refractory B-cell NHL                         NCT00312845                                                                   
  European Organisation for Research and Treatment of Cancer (EORTC)          Phase 3                                                             refractory or recurrent cutaneous TCL                     NCT01386398                                                                   
  Zhengang Yuan, Eastern Hepatobiliary Surgery Hospital, China                Phase 3                                                             Intrahepatic Cholangiocarcinoma                           NCT03345303                                                                   
  University Hospital Heidelberg                                              Phase 2                                                             AML                                                       NCT04173585                                                                   
  Millennium Pharmaceuticals                                                  Phase 2                                                             NSCLC                                                     NCT01833143                                                                   
  Tianjin Medical University General Hospital                                 Phase 2                                                             Neuromyelitis Optica Spectrum Disorder                    NCT02893111                                                                   
  Northwestern University National Heart, Lung, and Blood Institute (NHLBI)   Phase 2                                                             PF                                                        NCT02370693                                                                   
  Sidney Kimmel Cancer Center at Thomas Jefferson University                  Phase 2                                                             GVHD                                                      NCT00408928                                                                   
  Ixazomib                                                                    Millennium/Takeda Pharmaceuticals                                   Launched at 2015                                          MM                                    NCT03173092                             First oral proteasome inhibitor, marketed as Ninlaro."Breakthrough Therapy" status from the U.S.- FDA for relapsed and/or refractory AL amyloidosis.TEAE: thrombocytopenia, peripheral edema, peripheral neuropathy, nausea, diarrhea, constipation, vomiting, and back pain \[[@B135-ijms-21-05164],[@B147-ijms-21-05164]\].
  Millennium/Takeda Pharmaceuticals                                           Phase 3                                                             Relapsed or Refractory Systemic Light Chain Amyloidosis   NCT01659658                                                                   
  Takeda Pharmaceuticals                                                      Phase 2                                                             Immune Thrombocytopenia and Autoimmune Hemolytic Anemia   NCT03965624                                                                   
  Millennium/Takeda Pharmaceuticals                                           Phase 2                                                             Myeloid and Lymphoid Hematologic Malignancy               NCT03082677                                                                   
  Takeda Pharmaceuticals                                                      Phase 2                                                             MCL                                                       NCT03616782                                                                   
  Millennium Pharmaceuticals                                                  Phase 2                                                             Kidney Diseases andEnd stage Renal Disease                NCT03213158                                                                   
  Millennium Pharmaceuticals/NCI                                              Phase 2                                                             B-cell NHL                                                NCT02339922                                                                   
  Carfilzomib (Kyprolis)                                                      Proteolix/Onyx Pharmaceuticals, AbbVie, Genentech & others, Amgen   Launched at 2012                                          MM                                    NCT03934684                             Hematologic TEAE: thrombocytopenia and anemia.Nonhematologic TEAE: upper respiratory tract infections, fatigue, nausea, dyspnea, diarrhea, and pyrexia \[[@B148-ijms-21-05164],[@B149-ijms-21-05164]\].
  Amgen, Janssen, LP                                                          Phase 3                                                             RRMM                                                      NCT02412878                                                                   
  Onyx Therapeutics, Inc                                                      Phase 2                                                             MCL                                                       NCT02042950                                                                   
  SCRI Development Innovations, LLC, Amgen                                    Phase 2                                                             Neuroendocrine Cancer                                     NCT02318784                                                                   
  Onyx Therapeutics, Inc.                                                     Phase 2                                                             Refractory Renal Cell Carcinoma                           NCT01775930                                                                   
  Amgen                                                                       Phase 2                                                             Metastatic Castration-resistant Prostate Cancer           NCT02047253                                                                   
  Fred Hutchinson Cancer Research Center, NCI                                 Phase 2                                                             Chronic GVHD                                              NCT02491359                                                                   
  M.D. Anderson Cancer Center; Amgen                                          Phase 1                                                             MCL, TCL, DLBCL                                           NCT01926665                                                                   
  Marizomib                                                                   Nereus Pharmaceuticals/Celgene                                      Phase 3                                                   Glioblastoma                          NCT03345095                             TEAE: fatigue, nausea, diarrhea, vomiting, constipation, dizziness, infusion site pain, back pain, anorexia, anemia and dyspnea.Unlike bortezomib, did not induce the limiting toxicities *viz.* peripheral neuropathy, neutropenia and thrombocytopenia \[[@B150-ijms-21-05164]\].
  Celgene                                                                     Phase 2                                                             MM                                                        NCT00461045                                                                   
  NCI                                                                         Phase 2                                                             Anaplastic Ependymoma                                     NCT03727841                                                                   
  Celgene                                                                     Phase 1                                                             NSCLC, Pancreatic Cancer, Melanoma, Lymphoma, MM          NCT00667082                                                                   
  Oprozomib                                                                   Onyx Pharmaceuticals                                                Phase 1/2                                                 R and/or R MM                         NCT01832727                             TEAE: Hypotension, thrombocytopenia, anemia and diarrhea \[[@B151-ijms-21-05164]\].Well tolerated in combinations with pomalidomide and dexamethasone.
  Amgen                                                                       Phase 1/2                                                           Advanced HCC                                              NCT02227914                                                                   
  Amgen                                                                       Phase 1/2                                                           MM, WM                                                    NCT01416428                                                                   
  Amgen                                                                       Phase 1                                                             Solid Tumors                                              NCT01129349                                                                   
  ***Deubiquitination (DUB) inhibitors***                                                                                                                                                                                                                                                 
  VLX1570                                                                     Vivolux, Mayo Clinic                                                Phase 1/2                                                 MM                                    NCT02372240                             Death of 2 patients receiving two doses at 1.2 mg/kg due to fatal pulmonary toxicity \[[@B152-ijms-21-05164]\].
  ***NEDD8 activating enzyme (NAE) inhibitors***                                                                                                                                                                                                                                          
  Pevonedistat                                                                Millennium Pharmaceuticals                                          Phase 3                                                   AML                                   NCT03268954                             DLT: Transaminase elevation, orthostatic hypotension, rash and elevated alanine transaminase \[[@B153-ijms-21-05164]\].Cardiac failure and multiorgan failure observed at dose of 147 mg/m^2^.No DLT at doses \<50 mg/m^2^.
  NCI                                                                         Phase 2                                                             Metastatic Cholangiocarcinoma, HCC                        NCT04175912                                                                   
  University of Michigan Rogel Cancer Center                                  Phase 2                                                             NSCLC                                                     NCT03228186                                                                   
  NCI                                                                         Phase 2                                                             Myeloproliferative Neoplasm                               NCT03238248                                                                   
  Millennium Pharmaceuticals                                                  Phase 1                                                             Advanced Solid Tumors and Neoplasms                       NCT03057366                                                                   
  TAS-4464                                                                    Taiho Oncology                                                      Phase 1/2; Terminated                                     MM, HNL                               NCT02978235                             As of Dec 2019, discontinued for most indications.
  TAK-243                                                                     Takeda Pharmaceuticals                                              Phase 1                                                   Myelodysplastic Syndrome, AML, CMML   NCT03816319                             Phase 1 trial for AML, Myelodysplastic syndrome and CMML initiated in May 2019.
  Millennium Pharmaceuticals                                                  Phase 1; terminated                                                 Advanced Malignant Solid Tumors                           NCT02045095                                                                   

Abbreviations: AML---acute myeloid leukemia; CMML---chronic myelomonocytic leukemia; DLBCL---diffuse large B-cell lymphoma; DLT---dose limiting toxicity; GVHD---graft versus host disease; HCC---hepatocellular carcinoma; MCL---Mantle cell lymphoma; MM---Multiple myeloma; NHL---Non-Hodgkin lymphoma; NSCLC---non-small cell lung cancer; PF---Pulmonary Fibrosis; RRWM---relapsed and refractory Multiple myeloma; TCL---T-cell lymphoma; TEAE---Treatment-emergent adverse effects; WM---Waldenstrom macroglobulinemia.

4.2. Deubiquitination (DUB) Inhibitors {#sec4dot2-ijms-21-05164}
--------------------------------------

DUB inhibitors are also being explored as therapeutic interventions in specific cancers. DUB is accomplished by proteases that can cleave the isopeptide bond formed during ubiquitination. Vivolux identified a novel Ubiquitine Specific Proteases 14 (USP14) specific inhibitor, VLX1570, and it has entered phase 1/2 trial for MM (Combination therapy, Second-line therapy or greater), but was terminated due to dose-limiting toxicity (<https://clinicaltrials.gov/ct2/show/NCT02372240>) ([Table 4](#ijms-21-05164-t004){ref-type="table"}). Multiple groups like Nynex Therapeutics, AbbVie, Ubiquigent have reported promising DUB inhibitors at the preclinical stage, but as of date, none of them have reached clinical trials.

4.3. NAE (NEDD8 Activating Enzyme) Inhibitors {#sec4dot3-ijms-21-05164}
---------------------------------------------

NAE is a heterodimeric molecule that catalyzes the formation of neural precursor cell expressed, developmentally down-regulated 8 (NEDD8)---adenosine monophosphate (AMP). NEDD8 is a ubiquitin-like protein that modifies cellular targets in a pathway that is parallel to but distinct from ubiquitin modification \[[@B154-ijms-21-05164]\]. NEDDylation is crucial for the activation of Cullin-RING-E3 ubiquitin ligases that are critical for proteasome-mediated protein degradation. Thus, NAE is a desirable target for intervention as it acts upstream of proteasome and catalyzes the first step in the NEDDylation pathway \[[@B155-ijms-21-05164]\]. Unfortunately, this broad intervention may have associated side effects, and one needs to weigh the benefits to the toxicity ratio before taking them to the clinic.

Pevonedistat, first-in-class NAE inhibitor from Millennium Pharmaceuticals, is an AMP mimetic that forms stable covalent adducts with NEDD8 in NAE catalytic pocket and prevents subsequent NAE reaction. It has received orphan drug status for AML and Myelodysplastic syndromes (MDS). Pevonedistat combination study with Azacitidine was terminated in AML patient, but the preliminary results encouraged Takeda to consider phase 2 trial for high risk MS. They also explored the same combination in phase 3 study for low-risk AML, high-risk Chronic myelomonocytic leukemia (CMML), and high-risk MDS \[[@B156-ijms-21-05164]\] ([Table 4](#ijms-21-05164-t004){ref-type="table"}). Though, due to serious toxicity at higher doses, pevonedistat dose beyond 100 mg/m^2^ is not being considered for further investigation \[[@B153-ijms-21-05164]\]. Takeda had one more Millennium molecule TAK-243 in phase 1 for relapsed or refractory AML, refractory MDS, and CML (<https://clinicaltrials.gov/ct2/show/NCT03816319>), but the studies were probably discontinued. Similarly, TAS-4464 by Taiho Pharmaceutical was also discontinued in phase 1 for HM and solid tumors, due to business reasons (<https://clinicaltrials.gov/ct2/show/NCT02978235>).

5. Molecules Inhibiting Nuclear Translocation, DNA Binding and Transcriptional Activation of NF-κB {#sec5-ijms-21-05164}
==================================================================================================

Nuclear import and cytoplasmic export of NF-κB happens through p65 shuttling between cytoplasm and nucleus. As the shuttling is essential to sustain all p65 mediated transcriptional programs and as it is implicated in various disease conditions such as cancer, inflammatory, and autoimmune diseases, it becomes an attractive therapeutic target. After the release of p65 from IκB by stimulation, arginine and lysine-rich nuclear localization signals (NLS) of p65 interacts first with importin α and later with importin β to form a heterodimer. Ferrying of trimeric cytosolic NLS (cNLS)/importin α/β protein complex into the nucleus is facilitated through importin β interaction with nuclear pore complexes (NPCs). NF-κB activation is one of the highly controlled pathways, following the translocation of p65, the increased transcriptional activity eventually results in a negative feedback oscillatory loop for p65 export from the nucleus \[[@B157-ijms-21-05164],[@B158-ijms-21-05164],[@B159-ijms-21-05164]\].

The activated p65 interacts with DNA and stimulates the synthesis of IκBα mRNA and increase the nuclear concentration of IκBα. The increased IκBα protein binds and exports with free p65 and DNA detached p65. This negative feedback regulation is highly controlled by IκBβ and IκBγ. IκBα protein composes a nuclear export regulatory domain contains leucine-rich nuclear export signal (NES) at N terminal region that plays a pivotal role for cytoplasmic localization of p65. The export of p65 happens via the CRM1 (chromosome region maintenance 1/exportin1/Exp1/Xpo1)-dependent pathway upon the interaction of CRMI and IκBα protein at leucine-rich NES domain. CRM1 is an export receptor, facilitates the transport of large macromolecules including RNA and protein from the nuclear membrane to the cytoplasm. CRM1 binds the Ran protein bound to GTP, allowing for a conformational change that facilitates cargo protein to nuclear export ([Figure 3](#ijms-21-05164-f003){ref-type="fig"}) \[[@B157-ijms-21-05164],[@B158-ijms-21-05164],[@B159-ijms-21-05164]\].

The stimuli induced p65 activation is transient, however, it upregulates transactivation of target genes of diverse activities such as cell proliferation and inflammatory cytokine release. Signals between p65 and transcription factors facilitate controlled and efficient transactivation. Further, various post-translational modifications (PTM) including ubiquitination, acetylation, methylation, phosphorylation, and sumoylation of p65 play a vital role in the NF-κB activation outcomes. DNA:p65 binding determines NF-κB activation and it is affected interactions with coactivators and corepressors as well as p65 termination \[[@B112-ijms-21-05164],[@B160-ijms-21-05164]\].

Phosphorylation of p65 has also been implicated in NF-κB regulation and involves mainly serine and threonine sites. The phosphorylation sites are mostly located in the Rel homology domain (RHD) and the transactivation domains (TAD) and the activation results in either increased or decreased transcriptional activity. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate the acetylation of p65 at lysine sites via acetylation and deacetylation respectively. Lysine acetylation of p65 is a reversible process and it depends on coactivators such as p300 and CREB binding protein (CBP) \[[@B161-ijms-21-05164]\]. Tip60 (HIV Tat-interacting protein 60), a coactivator of NF-κB p65, enhances acetylation of Lys310 and upregulate p65 transcriptional activity through PPI. Moreover, Tip60 binds DNA prior to p65 and potentially modulates other cofactors interactions with p65 \[[@B162-ijms-21-05164]\]. The acetylation of specific lysine residue Lys122 \[[@B163-ijms-21-05164]\] and Lys123 decreases DNA binding of NF-κB p65 whereas Lys221 \[[@B38-ijms-21-05164]\] and Lys218 enhances the DNA binding of NF-κB p65. Lys310 acetylation is recognized by the two bromodomains of Brd4, which recruits activated CDK9 to phosphorylate RNA polymerase II for the transcription of a subset of NF-κB target genes \[[@B28-ijms-21-05164],[@B164-ijms-21-05164]\].

5.1. Nuclear Export Inhibitors {#sec5dot1-ijms-21-05164}
------------------------------

Leptomycin B (LMB), an irreversible CRM1 inhibitor covalently binds to cysteine 528 and directly blocks its interaction with the NES. LMB was tested for advanced refractory cancer, but was discontinued due to significant systemic toxicity and limited efficiency at phase 1. Later on, Karyopharm developed LMB analogue KOS-2464, but it has not been tested in a clinical setting so far \[[@B165-ijms-21-05164],[@B166-ijms-21-05164],[@B167-ijms-21-05164]\]. Synthetic CRM1 inhibitor (CBS9106) blocks the nuclear export by inducing CRM1 degradation via Neddylation pathway and at present, it is in phase1 trial for metastatic solid tumor. Structure-based drug design led to the further development of CRM1 small molecule inhibitors called as selective inhibitors of nuclear export (SINE) includes Selinexor (KPT-330), Verdinexor (KPT-335) and Eltanexor (KPT-8602) and these are orally bioavailable and highly selective. They are currently in clinical trials for various cancer conditions as standalone or in combination with other drugs. They are also found to be potential antiviral agents against various influenza strains and respiratory syncytial virus. Selinexor (KPT-330) got FDA approval in July 2019 for RRMM and is currently also taken into COVID-19 clinical trial \[[@B168-ijms-21-05164],[@B169-ijms-21-05164],[@B170-ijms-21-05164]\] ([Table 5](#ijms-21-05164-t005){ref-type="table"}).

ijms-21-05164-t005_Table 5

###### 

Clinical small molecules inhibitors targeting nuclear translocation, DNA binding, and transcriptional activation of NF-kB.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                  Originator/Developer                                         Stage                                       Indication                             Trail No                                Purpose/Other Information
  ----------------------------------------------------- ------------------------------------------------------------ ------------------------------------------- -------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***Selective inhibitors of nuclear export (SINE)***                                                                                                                                                                                           

  Selinexor                                             Karyopharm Therapeutics                                      Launched at 2019                            RRMM                                   NCT03110562                             Launched for DLBCL in 2020.Side effects include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia \[[@B171-ijms-21-05164]\].Thrombocytopenia addressed by platelet transfusions and thrombopoietin receptor agonists.Granulocyte colony stimulating factors were effective at resolving neutropenia.The central nervous system mediated anorexia with weight loss and malaise limits the frequency of dosing to two or three times per week.

  Phase 3                                               Endometrial Cancer                                           NCT03555422                                                                                                                

  Phase 2                                               Thymoma, Advanced thymic epithelial tumor                    NCT03193437                                                                                                                

  Phase 2                                               Coronavirus Infection                                        NCT04355676                                                                                                                

  Phase 2                                               Coronavirus Infection                                        NCT04349098                                                                                                                

  Phase 2                                               Myelofibrosis                                                NCT03627403                                                                                                                

  Phase 2                                               AML (Relapsed/Refractory)                                    NCT02249091                                                                                                                

  Phase 2                                               Ovarian, Endometrial and Cervical Carcinoma, Breast Cancer   NCT02025985                                                                                                                

  Preregistered/Phase 2                                 DLBCL                                                        NCT02227251; NCT03992339                                                                                                   

  Phase 1/2                                             Diabetic Foot Ulcers                                         NCT02367690                                                                                                                

  Phase 1/2                                             NSCLC                                                        NCT03095612                                                                                                                

  Phase 1                                               Colorectal Neoplasm                                          NCT02384850                                                                                                                

  Phase 1                                               BCL                                                          NCT02741388                                                                                                                

  Phase 1                                               Solid Tumors                                                 NCT02078349                                                                                                                

  Phase 1                                               Soft Tissue Sarcoma                                          NCT03042819                                                                                                                

  NCI                                                   Phase 1                                                      Gliosarcoma, Newly Diagnosed Glioblastoma   NCT04216329                                                                    

  Phase 1                                               Recurrent or Refractory Solid Tumors or High-Grade Gliomas   NCT02323880                                                                                                                

  Eltanexor                                             Karyopharm Therapeutics                                      Phase 2                                     RRMM, mCRC, mCRPC, HR-MDS              NCT02649790                             TEAE: Thrombocytopenia, neutropenia, anemia, leukopenia, and hyponatremia \[[@B172-ijms-21-05164]\].

  Verdinexor                                            Karyopharm Therapeutics                                      Phase 1                                     Healthy adults                         NCT02431364                             Conditional approval by US-FDA to treat canine lymphoma \[[@B173-ijms-21-05164]\].

  Felezonexor (SL-801)                                  Stemline Therapeutics                                        Phase 1                                     Solid Tumors                           NCT02667873                             Felezonexor showed partial response in the interim results for phase 1 study in microsatellite stable colorectal cancer.

  ***Histone deacetylase inhibitors***                                                                                                                                                                                                          

  Vorinostat                                            Merck                                                        Marketed                                    Cutaneous TCL                          NCT00875056, NCT00091559                TEAE: Thrombocytopenia, dehydration, pulmonary embolism, squamous cell carcinoma, and severe anemia \[[@B174-ijms-21-05164]\].There are reports of QTc-interval prolongation.

  Romidepsin                                            Celgene                                                      Marketed                                    Cutaneous and Peripheral TCL           NCT00426764                             TEAE; nausea, fatigue, anemia, thrombocytopenia, ECG T-wave changes, neutropenia, and lymphopenia \[[@B175-ijms-21-05164]\].

  Belinostat                                            Onxeo                                                        Marketed                                    Peripheral TCL                         NCT00274651                             TEAE: Nausea, fatigue, pyrexia, anemia, and vomiting \[[@B176-ijms-21-05164]\].

  Panobinostat                                          Novartis/Secura Bio                                          Marketed                                    MM                                     NCT01023308                             TEAE: Thrombocytopenia, neutropenia, lymphopenia, anemia, diarrhea, fatigue, and nausea \[[@B177-ijms-21-05164]\].

  Tucidinostat                                          HUYA Bioscience                                              Marketed                                    Peripheral TCL\                        NCT04040491                             TEAE: Thrombocytopenia, neutropenia, fatigue, leucopenia, vomiting, diarrhea, nausea, and anemia \[[@B178-ijms-21-05164]\].
                                                                                                                                                                 (different stages for other cancers)                                           

  ***DNA acetylation inhibitors***                                                                                                                                                                                                              

  Azacitidine                                           Pfizer/Celgene                                               Marketed                                    AML; CML; MDS                          NCT03416179, NCT03416179, NCT01201811   TEAE: Nausea, vomiting, diarrhea, and cytopenia \[[@B179-ijms-21-05164]\].Myelosuppression is also observed but usually transient.

  AbbVie/                                               Marketed                                                     MDS                                         NCT04401748                                                                    

  Decitabine                                            Janssen-Cilag/Otsuka Pharmaceutical                          Marketed                                    AML, MDS                               NCT02472145, NCT01751867                TEAE: Myelosuppression (neutropenia, thrombocytopenia, and anemia), Febrile neutropenia, pyrexia, fatigue, nausea, cough, petechiae, diarrhea, and constipation \[[@B180-ijms-21-05164]\].
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AML---acute myeloid leukemia; BCL----B-cell leukemia; CML---chronic myeloid leukemia; DLBCL---diffuse large B-cell lymphoma; HR-MDS---Higher Risk Myelodysplastic Syndrome; mCRC---Metastatic Colorectal Cancer; mCRPC---Metastatic Castration Resistant Prostate Cancer; MDS---Myelodysplastic Syndromes; MM---Multiple myeloma; NSCLC---non-small cell lung cancer; RRMM---relapsed and refractory Multiple myeloma; TCL---T-cell lymphoma; TEAE---Treatment-emergent adverse effects.

5.2. Nuclear Import Inhibitors {#sec5dot2-ijms-21-05164}
------------------------------

From the therapeutic view, nuclear export inhibitors are more explored in clinical settings than nuclear import inhibitors and the latter have not entered any clinical trial yet. Ivermectin, a marketed anti-protozoal drug, was later also found to be a specific importin α/β inhibitor. It was reported to show potential antiviral activity against both HIV-1 and dengue virus via inhibiting importin α/β interaction with HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively \[[@B181-ijms-21-05164]\]. Importazole was reported to be an importin β inhibitor in Xenopus egg extracts and cultured cells in vitro assay \[[@B182-ijms-21-05164]\]. Cell permeable synthetic peptide (SN50) carries a functional domain to inhibit the NLS of p65/p50 and prevent the complex nuclear translocation \[[@B183-ijms-21-05164]\]. Anti-inflammatory peptide-6 (AIP6) showed anti-inflammatory activity in both in-vitro and in-vivo experiments and mechanistically it inhibited p65/p50 translocation and DNA binding \[[@B184-ijms-21-05164]\].

5.3. Inhibition of p65 Transactivation and DNA Binding {#sec5dot3-ijms-21-05164}
------------------------------------------------------

The p65 has acidic TAD in the carboxyl-terminal end and it is essential for the regulation of the p65 target gene. Activated p65 TAD through phosphorylation enhances protein-protein interaction and interact with 27 various co-transcriptional regulators such as TBP, p300 and ATR etc. \[[@B185-ijms-21-05164]\]. For the therapeutic interventions, competing p65 peptide has been used to encompass the TAD and to inhibit conformational changes that further prevent transactivation of p65. Synthetic peptide, GILZ (glucocorticoid-induced leucine zipper) mimetic and Smad4-binding domain peptide encompasses the TAD and inhibit the transactivation. Currently, there are no small molecule inhibitors available that target p65 TAD. Similarly decoy NF-kB nucleotides bind with p65 RHD which further inhibits the interaction of p65 with cis-elements of the target gene in the DNA. At present, no small molecule is developed to modify interaction \[[@B186-ijms-21-05164],[@B187-ijms-21-05164]\].

5.4. Inhibition of Post-Translational Modifications {#sec5dot4-ijms-21-05164}
---------------------------------------------------

Various transcriptional factors regulate gene expression through PMTs, where NF-κB is one of the important transcriptional factors regulates gene expression via PMTs. Transcriptional activities of NF-kB are regulated by many PMTs such as acetylation, ubiquitination, phosphorylation, methylation, sulfydration, nitrosylation, and sumoylation. Reversible acetylation is one of the important PMT for p65 and it is mainly regulated by HAT and HDAC enzymes. Acetylation of p65 happens predominately on lysine residue mainly by transcriptional coactivators p300/CBP and some lysine residues by PCAF \[[@B163-ijms-21-05164],[@B186-ijms-21-05164],[@B188-ijms-21-05164]\]. Modulation of reversible acetylation is extensively explored for therapeutic intervention, particularly HAT and HDAC enzymes. To date, many HAT and HDAC inhibitors are approved or in ongoing clinical trials for various indications. Similarly, DNA methylation is another important PMTs regulated by DNA methyltransferases (DNMT) and inhibitors of DNMT are currently in many clinical trials for various indications. For the last two decades, a considerable number of epigenetic-targeted small molecules got FDA approval, such as Azacitidine, Decitabine, Vorinostat, Romidepsin, Belinostat, Panobinostat, and Tucidinostat for various therapeutic indications. Especially HDAC inhibitors studied extensively in drug discovery and few of them approved in the clinic \[[@B189-ijms-21-05164]\] ([Table 5](#ijms-21-05164-t005){ref-type="table"}).

6. Molecules that Can or May be Repurposed as NF-κB Pathway Inhibitors {#sec6-ijms-21-05164}
======================================================================

In addition to the small molecules that were designed to inhibit specific targets in NF-κB pathways, many that were pursued for unrelated targets were later also found to inhibit NF-κB signaling. As discussed earlier, many molecules like Dasatinib, Olafertinib and Pacritinib were originally intended for other targets. It should be noted that in these the intended therapeutic actions may very well be an outcome of synergistic inhibition of all the targets. There are still other classes of compounds where the drugs marketed of an unrelated indication are later found to inhibit NF-κB pathways and may be repurposed for the same. We have already discussed DMARD like Sulfasalazine and NSAID like Aspirin and Salicylate reported to have IKKα inhibitory activity. Gabexate marketed as Anticoagulant was also found to be effective in treating patients with sepsis-associated TNFα mediated disseminated intravascular coagulation. It was proposed \[[@B190-ijms-21-05164]\] to inhibit binding of AP1 and of NF-κB to their respective target inhibiting activation of mitogen-activated protein kinase (MAPK) pathways and prevent proteolytic degradation of IκBα.

Glucocorticoids (Prednisolone and Vamorolone) are well known for their potent anti-inflammatory activities \[[@B191-ijms-21-05164]\] (<https://www.reveragen.com/vamorolone/>). Their binding to cytoplasmic nuclear hormone receptor (glucocorticoid receptor) was reported to have a transrepression activity and they are also known to repress the action of NF-κB gene activation. Macrolides (Erythromycin and Azithromycin) are also reported \[[@B192-ijms-21-05164]\] for their anti-inflammatory activity as they downregulate cytokine gene expression by inhibiting transcriptional activation of NF-κB. These molecules were originally designed and are being marketed for more than a decade as antibacterial drugs. The activity of these 14-15 member macrolides has propelled research into 12 member analogs that do not show their original antibacterial activity but retain anti-inflammatory properties \[[@B193-ijms-21-05164]\]. Existing know-how of macrolides can assist these analogs in their discovery and development stages.

Polyphenols like curcumin, capsaicin, apigenin, oleandrin, quercetin, resveratrol, cinnamaldehyde, epigallocatechin-3-gallate, etc. are well known for their anti-inflammatory properties \[[@B194-ijms-21-05164],[@B195-ijms-21-05164],[@B196-ijms-21-05164]\] and mostly act through arachidonic acid dependent and independent pathways. While the former involves COX, the latter is generally mediated through NF-κB. They inhibit the NF-κB signaling by either preventing IκB degradation by inhibiting phosphorylation or ubiquitination of relevant kinases or inhibiting the interaction of NF-κB subunits with DNA.

Iguratimod, a disease modified anti-rheumatic drug (DMARD) is known to inhibit the production of immunoglobulins and cytokines and regulate T lymphocyte subsets at the synovial joints \[[@B197-ijms-21-05164]\]. Iguratimod was also reported \[[@B198-ijms-21-05164]\] to inhibit nuclear translocation of NF-κB p65. Mepacrine is an antiprotozoal, antirheumatic, and an intrapleural sclerosing agent. Apart from histamine N-methyltransferase inhibitory activity, it is a DNA intercalating agent that also inhibits the NF-κB pathway \[[@B199-ijms-21-05164]\]. Dimethyl fumerate (one of the active ingredient of Fumaderm) is prescribed for Psoriasis and relapsing multiple sclerosis. One of their mode of action is by interacting with glutathione that leads to the inhibition of NF-κB nuclear translocation and its transcriptional activity \[[@B200-ijms-21-05164]\]. It was reported to inhibit nuclear translocation of NF-κB p50/p65 heterodimers.

7. Conclusions and Way Forward {#sec7-ijms-21-05164}
==============================

NF-κB pathways play a critical role in almost all chronic diseases and are well-studied and mapped out. They involve multiple players that not only play key roles in signaling, but also are targetable from a drug discovery aspect. This has prompted researchers all over the world to explore thousands of molecules for modulating this pathway. As of date many of these potent drugs are in clinical trials or launched successfully ([Figure 4](#ijms-21-05164-f004){ref-type="fig"}) for diverse therapeutic intervention. Added to this many of the drugs that are currently in use with an unknown or different mechanism was later shown to modulate this pathway also. This is especially true for small molecules that often participate in multiple modes of action. Identification of established drugs showing additional NF-κB activity has led to the repurposing of drugs for new indications and thus further propelled research in this field.

Looking forward, we will definitely see more compounds that inhibit NF-κB pathways that not only will qualify for clinical trials but also get approved for administration in patients. As our understanding of the pathway improves, we will see more focus research in the area of designing inhibitors to their therapeutic area of applications. We anticipate that compounds, instead of getting broad coverage, will be focusing on specific indications or even subtypes. With proper patient stratifications using relevant biomarkers \[[@B201-ijms-21-05164]\], inhibitors of BTK, IRAK, cIAP, PI3K, and even AKT and NAE will see more success in clinical trials. IKK complex inhibitors, one of the main focus of the research due to its central role in NF-κB pathways is challenged by the failure of IKKα/IKKβ inhibitors in the clinic. More selective non-ATP competitive inhibitors, use of isoform-specific readouts to differentiate the role of IKKα vs. IKKβ in cellular activity, and appropriate therapeutic application should lead to more clinical success. Alternatively, inhibition of IKKγ that leads to lower ADR will be more beneficial. The clinical success of IKKγ inhibitors and for other such peptides/pseudopeptides modulated targets, will in turn depend on strategies to overcome the proteasomal degradation and delivery to the site of action. Furthermore, targeting the disease-specific downstream effector of the unregulated NF-κB pathway provides a much safer alternative. Gadd45β (growth arrest and DNA damage 45B)/MKK7 interaction suppresses MKK7/JNK-induced apoptosis and promotes proliferation in cancerous cells. DTP3, a D-tripeptide inhibitor disrupts this interaction and induces apoptosis of cancerous cells \[[@B25-ijms-21-05164]\]. Unlike upstream targets, targeting this should be less toxic to healthy cells. Imperial College London was exploring a Phase 1/2 dose-escalation study in patients with RRMM \[[@B202-ijms-21-05164]\] but not much progress has been reported. For synthetic lethal targets like TBK1 and ATM, clinical trials in disease with specific mutations or studies with relevant combinations are being explored for success. In a few other targets, biology is still in the grey area and their role in modulating the disease, especially in the clinic is yet to be established. NIK is one such example where appropriate indication (beyond MM) or relevant combination needs to be worked out for clinical consideration. Last but definitely not the least, drugs in use that additionally showed NF-κB activity should be actively explored and be used as templates as novel scaffolds.
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![Schematic diagram of the canonical and non-canonical Nuclear factor kappa B (NF-κB) signaling pathways. Canonical NF-κB signaling cascade is initiated at the cell membrane through tumor necrosis factor --α receptor (TNFR), interleukin1 receptor (IL1R), toll-like receptor (TLR), T-cell receptors (TCR), B-cell receptors (BCR), and growth factor receptors (GFR) while the non-canonical pathway can be stimulated via receptors such as lymphotoxin α and β (LTA and B), cluster of differentiation 40 (CD40) and B-cell activating factor (BAFF). Upon stimulation of the receptor, the canonical pathway is mediated through adapter proteins and kinases that eventually activate the IκB kinase (IKK) complex via activation of transforming growth factor β-activated kinase 1 (TAK1). Similarly, PI3K mediates signaling from GFR, TLRs, TCR, BCR, and cytokines feeds into activation of IKK via phosphorylation of AKT (protein kinase B) and IKKα. Subsequently, polyubiquitination and site-specific phosphorylation of IκB protein via IKK complex leads to its proteasomal degradation. The released NF-κB dimers translocate to the nucleus. Meanwhile, during the activation of the non-canonical pathway, TNF receptor-associated factor (TRAF) and cellular inhibitor of apoptosis (c-IAP) are recruited to the receptor as TRAF2/TRAF3/c-IAP1/2 complex. TRAF2/TRAF3 undergo proteasomal degradation allowing NF-κB-inducing kinase (NIK) levels to be stabilized. NIK then phosphorylates IKKα homodimer. Activated IKKα homodimer phosphorylates p100, leading to the partial degradation of p100 to p52. RelB/p52 heterodimers translocate to nucleus for further transcription.](ijms-21-05164-g001){#ijms-21-05164-f001}

![Canonical & non-canonical NF-κB pathway and the site of interventions currently being explored for therapeutic benefit.](ijms-21-05164-g002){#ijms-21-05164-f002}

![p65 shuttling and the current therapeutic targets explored in the pathway. After ubiquitination IkB, translocation of p65/p50 (Cargo) happens via arginine and lysine-rich NLS (Nuclear localization signals) of p65 interaction with importin α/β heterodimer. This trimeric protein complex (cNLS/importin α/β protein) ferrying into the nucleus is facilitated through importin β interaction with nuclear pore complexes (NPCs). Whereas export of p65 via the CRM1-dependent pathway upon interaction with leucine-rich NES. CRM1 is an export receptor, facilitates the transport of large macromolecules including RNA and protein from the nuclear membrane to the cytoplasm. CRM1 binds the Ran protein bound to GTP, allowing for a conformational change that facilitates cargo protein to nuclear export. Nuclear import and export inhibitors preclude the p65 shuttling via NLS and NES, respectively.](ijms-21-05164-g003){#ijms-21-05164-f003}

![(**A**) Percentage distribution of small molecule inhibitors from various targets in NF-κB pathways reached in the clinic for different indications. (**B**) Similarly, the number of small molecule inhibitors from various targets in NF-κB pathways placed in phase 1(P1), phase 2(P2), phase 3(P3), and launched (L) in clinical trials.](ijms-21-05164-g004){#ijms-21-05164-f004}
